Neuronal Histamine and its Receptors: Implication of the Pharmacological Treatment of Obesity

被引:16
作者
Masaki, T. [1 ]
Yoshimatsu, H. [1 ]
机构
[1] Oita Univ, Fac Med, Dept Internal Med 1, Oita 8795593, Japan
关键词
Histamine; food intake; obesity; histamine H(1) receptors; histamine H(3) receptors; histidine decarboxylase; brain; SUPPRESSES FOOD-INTAKE; MESSENGER-RNA LEVELS; INDUCED WEIGHT-GAIN; H-3; RECEPTOR; UCP FAMILY; TARGETED DISRUPTION; FAT ACCUMULATION; BRAIN HISTAMINE; FEEDING RHYTHM; BODY-WEIGHT;
D O I
10.2174/092986710794182944
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Obesity is the effect of imbalance between energy intake and expenditure and forms a fundamental basis of the metabolic syndrome. A number of substances implicated in the regulation of energy metabolism represent opportunities for anti-obesity drug development. Neuronal histamine and its receptors have been shown to regulate energy metabolism and are considered as anti-obesity targets. Several histamine receptor subtypes have been identified; of these, histamine H(1) and H(3) receptors (H(1)-R and H(3)-R) have been specifically recognized as mediators of energy intake and expenditure. In addition, several histamine drugs related to H(1)-R and H(3)-R, have been shown to attenuate body weight gain both in rodent and human. These results provide the reagents for histamine receptors biology and may find applications in the treatment of obesity and related metabolic disorders. In this review, the development of agonists and antagonists of histamine receptors are provided.
引用
收藏
页码:4587 / 4592
页数:6
相关论文
共 56 条
[1]  
[Anonymous], J PSYCHOSOC NURS
[2]   AUTO-INHIBITION OF BRAIN HISTAMINE-RELEASE MEDIATED BY A NOVEL CLASS (H-3) OF HISTAMINE-RECEPTOR [J].
ARRANG, JM ;
GARBARG, M ;
SCHWARTZ, JC .
NATURE, 1983, 302 (5911) :832-837
[3]   The H3 receptor is involved in cholecystokinin inhibition of food intake in rats [J].
Attoub, S ;
Moizo, L ;
Sobhani, I ;
Laigneau, JP ;
Lewin, MJM ;
Bado, A .
LIFE SCIENCES, 2001, 69 (04) :469-478
[4]   Effect of histaminergic manipulation on weight in obese adults: a randomized placebo controlled trial [J].
Barak, N. ;
Greenway, F. L. ;
Fujioka, K. ;
Aronne, L. J. ;
Kushner, R. F. .
INTERNATIONAL JOURNAL OF OBESITY, 2008, 32 (10) :1559-1565
[5]  
Barak N, 2008, EXPERT OPIN INV DRUG, V17, P795, DOI [10.1517/13543784.17.5.795, 10.1517/13543784.17.5.795 ]
[6]   Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist [J].
Barbier, AJ ;
Berridge, C ;
Dugovic, C ;
Laposky, AD ;
Wilson, SJ ;
Boggs, J ;
Aluisio, L ;
Lord, B ;
Mazur, C ;
Pudiak, CM ;
Langlois, X ;
Xiao, W ;
Apodaca, R ;
Carruthers, NI ;
Lovenberg, TW .
BRITISH JOURNAL OF PHARMACOLOGY, 2004, 143 (05) :649-661
[7]   The physiology of brain histamine [J].
Brown, RE ;
Stevens, DR ;
Haas, HL .
PROGRESS IN NEUROBIOLOGY, 2001, 63 (06) :637-672
[8]   Histamine H3 receptor antagonists reach out for the clinic [J].
Celanire, S ;
Wijtmans, M ;
Talaga, P ;
Leurs, R ;
de Esch, IJP .
DRUG DISCOVERY TODAY, 2005, 10 (23-24) :1613-1627
[9]   Pharmacogenetics of antipsychotic-induced weight gain [J].
Correll, CU ;
Malhotra, AK .
PSYCHOPHARMACOLOGY, 2004, 174 (04) :477-489
[10]   4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention [J].
Cowart, M ;
Faghih, R ;
Curtis, MP ;
Gfesser, GA ;
Bennani, YL ;
Black, LA ;
Pan, LP ;
Marsh, KC ;
Sullivan, JP ;
Esbenshade, TA ;
Fox, GB ;
Hancock, AA .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (01) :38-55